Dianhe Li1, Xiaoxia Zhu1, Haofei Wang2, Min Qiu3, Na Li1. 1. Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. 2. Department of Cardiothoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. 3. School of Public Health and Tropical Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Abstract
BACKGROUND: We performed a meta-analysis to compare overall survival (OS) outcomes in patients with synchronous oligometastatic non-small cell lung cancer (NSCLC) who underwent aggressive thoracic therapy (ATT) with those who did not. METHODS: A systematic review of controlled trials of ATT on survival in synchronous oligometastatic NSCLC was conducted. Hazard ratio (HR) for the main endpoint OS was pooled using a fixed-effects model. Subgroup analysis was performed in patients with single organ metastases, or with different numbers of brain metastases, or with different stages of thoracic disease. Pooled survival curves of OS were constructed. RESULTS: Seven eligible retrospective observational cohort studies were identified including 668 synchronous oligometastatic NSCLC patients, of whom 227 (34.0%) received ATT. For patients with synchronous oligometastatic NSCLC, ATT was associated with a significant improvement of OS (HR, 0.48; 95% CI, 0.39-0.60; P<0.00001). In subgroup analysis, the association with OS was similar or even strengthened, with a HR of 0.42 (95% CI, 0.31-0.56) in single organ metastases group, 0.49 (95% CI, 0.31-0.75) in solitary brain metastasis group, and 0.38 (95% CI, 0.20-0.73) in thoracic stage I-II group, respectively. The pooled cumulative survival rates for patients received ATT were 74.9% at 1 year, 52.1% at 2 years, 23.0% at 3 years, and 12.6% at 4 years. The corresponding pooled survival for patients who did not receive ATT were 32.3%, 13.7%, 3.7%, and 2.0%, respectively. CONCLUSIONS: Survival benefit from ATT is common in synchronous oligometastatic patients. Selected patients with synchronous oligometastatic NSCLC could also achieve long-term survival with ATT.
BACKGROUND: We performed a meta-analysis to compare overall survival (OS) outcomes in patients with synchronous oligometastatic non-small cell lung cancer (NSCLC) who underwent aggressive thoracic therapy (ATT) with those who did not. METHODS: A systematic review of controlled trials of ATT on survival in synchronous oligometastatic NSCLC was conducted. Hazard ratio (HR) for the main endpoint OS was pooled using a fixed-effects model. Subgroup analysis was performed in patients with single organ metastases, or with different numbers of brain metastases, or with different stages of thoracic disease. Pooled survival curves of OS were constructed. RESULTS: Seven eligible retrospective observational cohort studies were identified including 668 synchronous oligometastatic NSCLCpatients, of whom 227 (34.0%) received ATT. For patients with synchronous oligometastatic NSCLC, ATT was associated with a significant improvement of OS (HR, 0.48; 95% CI, 0.39-0.60; P<0.00001). In subgroup analysis, the association with OS was similar or even strengthened, with a HR of 0.42 (95% CI, 0.31-0.56) in single organ metastases group, 0.49 (95% CI, 0.31-0.75) in solitary brain metastasis group, and 0.38 (95% CI, 0.20-0.73) in thoracic stage I-II group, respectively. The pooled cumulative survival rates for patients received ATT were 74.9% at 1 year, 52.1% at 2 years, 23.0% at 3 years, and 12.6% at 4 years. The corresponding pooled survival for patients who did not receive ATT were 32.3%, 13.7%, 3.7%, and 2.0%, respectively. CONCLUSIONS: Survival benefit from ATT is common in synchronous oligometastaticpatients. Selected patients with synchronous oligometastatic NSCLC could also achieve long-term survival with ATT.
Authors: Cynthia Villarreal-Garza; Dolores de la Mata; Diego G Zavala; Eleazar O Macedo-Perez; Oscar Arrieta Journal: Clin Lung Cancer Date: 2012-06-07 Impact factor: 4.785
Authors: Pasi A Jänne; Xiaofei Wang; Mark A Socinski; Jeffrey Crawford; Thomas E Stinchcombe; Lin Gu; Marzia Capelletti; Martin J Edelman; Miguel A Villalona-Calero; Robert Kratzke; Everett E Vokes; Vincent A Miller Journal: J Clin Oncol Date: 2012-04-30 Impact factor: 44.544
Authors: Todd W Flannery; Mohan Suntharalingam; William F Regine; Lawrence S Chin; Mark J Krasna; Michael K Shehata; Martin J Edelman; Marnie Kremer; Roy A Patchell; Young Kwok Journal: Int J Radiat Oncol Biol Phys Date: 2008-02-14 Impact factor: 7.038
Authors: Oscar Arrieta; Cynthia Villarreal-Garza; Jesús Zamora; Mónika Blake-Cerda; María D de la Mata; Diego G Zavala; Saé Muñiz-Hernández; Jaime de la Garza Journal: Radiat Oncol Date: 2011-11-25 Impact factor: 3.481
Authors: Rafael A S Fernandez; Rainbow W H Lau; Jacky Y K Ho; Peter S Y Yu; Simon C Y Chow; Innes Y P Wan; Calvin S H Ng Journal: J Thorac Dis Date: 2019-04 Impact factor: 2.895
Authors: Derek P Bergsma; Michael J Moravan; Jaipreet S Suri; Michael A Cummings; Kenneth Y Usuki; Deepinder P Singh; Michael T Milano Journal: J Thorac Dis Date: 2022-06 Impact factor: 3.005
Authors: Alicia Román-Jobacho; María Hernández-Miguel; María Jesús García-Anaya; Jaime Gómez-Millán; J A Medina-Carmona; Ana Otero-Romero Journal: J Clin Transl Res Date: 2021-05-27
Authors: Derek P Bergsma; Joseph K Salama; Deepinder P Singh; Steven J Chmura; Michael T Milano Journal: Front Oncol Date: 2017-09-19 Impact factor: 6.244